Background: Recent studies suggest that magnesium, which specially affects the N-methyl-D-aspartate receptor response to excitatory amino acids, may be a supportive therapeutic agent in Alzheimer’s disease. Objective: To investigate the relationship between magnesium levels and the cognitive test results and clinical stages of the patients. Methods: Thirty-seven patients (20 women, 17 men) and 34 controls were included in the study. The patients were staged according to Global Deterioration Scale (GDS) and Clinical Dementia Rating (CDR). Results: There was a significant difference for Mg levels according to GDS (p = 0.030). Similarly, Mg levels were different between patients with low and high CDR stages (p = 0.003). Mg levels were lower in the group whose MMSE scores were <20 than in those whose MMSE scores were ≧20. A negative correlation was found between Mg levels and GDS and CDR (respectively: r = –0.35, p = 0.033; r = –0.360, p = 0.029). Conclusion: Our data suggest that there is a relationship between serum Mg levels and the degree of Alzheimer’s disease and that the determination of the Mg level at various stages may provide valuable information in further understanding the progression and treatment of Alzheimer’s disease.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.